Pilocarpine veterinary grade is formulated as a sterile aqueous ophthalmic solution at 1%, 2%, and 4% for miotic induction and intraocular pressure control in dogs, cats, and horses where muscarinic receptor agonism is clinically indicated. Pilocarpine hydrochloride is preferred over pilocarpine nitrate in ophthalmic compounding because its aqueous solubility at 20°C exceeds 250 mg/mL, reducing the volume of water for injection required to reach target concentration. The bulk solution is prepared in glass-lined equipment under nitrogen blanketing and adjusted with acetate buffer to pH 3.5–5.5; lactone ring hydrolysis to pilocarpic acid becomes measurable above pH 6.0 and accelerates rapidly above pH 7.0. Sodium chloride is used as the tonicity agent to maintain osmolality between 290 mOsm/kg and 310 mOsm/kg. Benzalkonium chloride at 0.1 mg/mL is included as a preservative for multidose containers; concentrations above 0.15 mg/mL are excluded because of corneal epithelial toxicity. Disodium edetate at 0.1 mg/mL is added as a metal-ion chelator to suppress trace-metal-catalyzed oxidative degradation. Sterilization is performed by membrane filtration through 0.22 µm polyvinylidene fluoride cartridges. Terminal autoclaving at 121°C for 15 min is avoided for ophthalmic solution when bulk pH exceeds 5.0, because epimerization to isopilocarpine increases under these conditions. Filling is performed in an ISO 14644-1 Class 5 environment into low-density polyethylene dropper bottles or polypropylene vials. Finished product testing includes sterility by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <789>, pH by USP <791>, and osmolality by USP <785>. Label storage is 15–25°C with protection from light, because ultraviolet irradiation below 400 nm generates photodegradation products.

What Limits Content Uniformity in Low-Dose Pilocarpine Tablets for Canine Use?

Low-dose pilocarpine tablets for canine sicca support are manufactured at strengths of 1 mg, 2 mg, and 5 mg per unit. Because the API mass fraction in the tablet core is 0.5–2.0 wt%, direct compression is not employed; segregation during hopper flow on rotary tablet presses increases content uniformity RSD above 6.0%. Dry granulation is used instead to avoid aqueous granulation fluid that would promote lactone ring hydrolysis. Pilocarpine hydrochloride is first diluted geometrically with microcrystalline cellulose at 50–60 wt%, lactose monohydrate at 20–30 wt%, and crospovidone at 2–5 wt%. The preblend is passed through a roller compactor at roll pressure 4–6 kN/cm and roll speed 3 rpm. The compacted ribbons are milled through a 1.0 mm screen to form granules. Residual moisture is controlled below 1.5% by Karl Fischer titration before compression. Magnesium stearate at 0.5–1.0 wt% is added as an external lubricant and mixed for 3–5 min at 12 rpm. Tablets are compressed on a rotary tablet press with 6 mm round concave punches to hardness 4–8 kp. Friability is controlled below 1.0% by USP <1216>. Disintegration is measured by USP <701> in 0.1 N hydrochloric acid at 37°C with a limit of ≤15 min. Dissolution is tested by USP <711> Apparatus II at 50 rpm in 500 mL of 0.1 N hydrochloric acid; the Q value is ≥80% at 30 min. Content uniformity is assessed by USP <905> with an acceptance value of ≤15.0 for low-strength units. Assay and related substances are determined by reversed-phase HPLC with UV detection at 215 nm; the method is validated for specificity, linearity, and precision according to ICH Q2(R1). Sodium starch glycolate and sodium bicarbonate are excluded from the formulation because their alkaline microenvironment raises local pH and accelerates pilocarpine ring opening to pilocarpic acid.

When Parenteral Pilocarpine Is Required for Salivary Stimulation in Adult Cattle or Horses

Parenteral pilocarpine hydrochloride is compounded as a sterile solution at 10 mg/mL or 20 mg/mL for veterinary use in adult cattle and horses when muscarinic receptor agonism is indicated to increase salivary and gastrointestinal secretions. The vehicle is water for injection, and the final pH is adjusted with dilute hydrochloric acid to 3.0–5.0. Sodium chloride is added to achieve osmolality between 270 mOsm/kg and 330 mOsm/kg. Benzyl alcohol at 1.0 wt% is used as a bacteriostatic agent in multidose vials, but it is omitted from intravenous formulations for horses because of the risk of neurotoxicity. The solution is sterile-filtered through 0.22 µm PVDF membranes and filled into Type I borosilicate glass vials under nitrogen. Steam sterilization at 121°C for 15 min is used only when the solution pH remains below 5.0 and headspace oxygen is below 2%; otherwise aseptic filtration is selected to limit isopilocarpine formation. The finished injection is inspected for visible particulates by USP <790> and tested for subvisible particulates by USP <788>. Sterility is confirmed by USP <71>, and bacterial endotoxin content is controlled by USP <85> with a limit of ≤0.5 EU/mg. The injectable solution is incompatible with alkaline admixtures such as sodium bicarbonate 8.4% because pilocarpine hydrolyzes rapidly above pH 6.0. Unpreserved vials are stored at 2–8°C, while preserved multidose configurations may be stored at 15–25°C. This veterinary formulation is compounded extemporaneously in many jurisdictions because no approved commercial parenteral pilocarpine product exists for food-producing species. Withdrawal periods are not established in food-producing animals, and this limitation must appear in the pharmaceutical risk assessment and the compounded preparation label.

Oral powders and granules containing pilocarpine hydrochloride are prepared as single-dose sachets or jar configurations for companion-animal dose titration where accurate low-dose administration is required. The finished powder contains pilocarpine hydrochloride at 1.0 mg/g to 5.0 mg/g in a carrier system based on anhydrous lactose or spray-dried maltodextrin. Colloidal silicon dioxide at 0.5–1.0 wt% is included to reduce electrostatic adhesion and improve flow through volumetric powder fillers. Butylated hydroxyanisole at 0.1–0.2 wt% is added to formulations intended for storage longer than 6 months at 25°C/60% RH to limit oxidative discoloration. Mixing is performed in a V-blender at 15 rpm for 10–20 min under controlled relative humidity below 40%. The API is introduced by geometric dilution with an equal mass of carrier, and the mixture is further diluted stepwise until the full batch size is reached. After blending, the powder is passed through an 850 µm screen to break agglomerates and packed in aluminum-foil laminate sachets with silica gel desiccant. Blend uniformity is tested by USP <905> using stratified sampling; the RSD must not exceed 5.0%. Residual moisture is controlled below 2.0% by Karl Fischer titration. Microbial quality is assessed by USP <61> and USP <62>. The powder is mixed with soft food immediately before administration; direct dry oral administration is not recommended because the bitter taste of pilocarpine can induce emesis or refusal.

Capsule Filling and Shell Compatibility Under Low-RH Conditions

Hard gelatin capsules containing pilocarpine hydrochloride are filled at strengths of 1 mg, 2 mg, and 4 mg for feline and canine patients. The fill formulation contains pregelatinized starch at 50–60 wt%, microcrystalline cellulose at 30–40 wt%, sodium lauryl sulfate at 0.1–0.3 wt%, and magnesium stearate at 0.25–0.5 wt%. Fill weight in a size 3 hard gelatin capsule is 100–120 mg. Sodium starch glycolate is avoided because its alkaline residue can raise the microenvironmental pH of the powder bed and accelerate lactone ring opening in the presence of residual moisture. Blending and encapsulation are conducted at 25°C and 35–40% RH; gelatin shells become brittle below 35% RH and soften above 60% RH. Filling is performed on an intermittent-motion capsule filler with tamping pins adjusted to maintain fill weight variation ±10% for 100 mg fills. Weight variation is evaluated by USP <905>. Dissolution is tested by USP <711> Apparatus I at 100 rpm in 900 mL of 0.1 N hydrochloric acid; release is ≥80% at 30 min. Disintegration is measured by USP <701> in 0.1 N hydrochloric acid at 37°C with a limit of ≤15 min. The capsule shell reduces light-induced degradation, but the finished product is still stored below 25°C and protected from humidity. Gelatin cross-linking is monitored as a delay in disintegration and indicates improper warehouse conditions or shell incompatible moisture ingress.

Dry Premix Blending Requires Geometric Dilution and Moisture Exclusion

Premix intermediates for veterinary pilocarpine are produced for subsequent dilution into oral powders, capsules, or in-clinic suspensions. The premix API concentration is normally 1.0–5.0% by weight. Lactose monohydrate, mannitol, or calcium phosphate dibasic dihydrate is used as the diluent; mannitol is preferred when the final intermediate will be reconstituted in water because it is compatible with acidic solution conditions and does not generate reducing sugars. Mixing is performed in a twin-shell blender at 15 rpm for 10–15 min after a geometric dilution sequence. The API is first combined with an equal mass of diluent for 3 min; the mixture is then diluted stepwise with equal masses until the full batch size is reached. A final screening through 500 µm mesh removes agglomerates and ensures uniform particle distribution. The process environment is maintained below 40% RH because pilocarpine hydrochloride adsorbs atmospheric moisture above 45% RH and becomes sticky during transfer. The premix is stored in double polyethylene liners inside a fiber drum with desiccant. Blend uniformity is verified with 10 sampling points by USP <905>; RSD should be ≤5.0%. Residual solvents are controlled by USP <467>. The premix is not intended for direct feed use in food-producing species because published data for this specific configuration is limited and withdrawal periods have not been established.